1. Development of the autoinflammatory disease damage index (ADDI)
- Author
-
The EUROFEVER participants, Annink, K, ter Haar, N, Gattorno, M, Lachmann, H, Kuemmerle-Deschner, J, Ozen, Seza, Goldbach-Mansky, R, Durrant, K, Alberighi, O Della Casa, Frenkel, J, and Çocuk Sağlığı ve Hastalıkları
- Subjects
medicine.medical_specialty ,Pathology ,Mevalonate kinase deficiency ,business.industry ,Cryopyrin-associated periodic syndrome ,Familial Mediterranean fever ,Inflammation ,Context (language use) ,medicine.disease ,Systemic inflammation ,Rheumatology ,Internal medicine ,Poster Presentation ,Pediatrics, Perinatology and Child Health ,Immunology ,medicine ,Immunology and Allergy ,Pediatrics, Perinatology, and Child Health ,Autoinflammatory disease ,medicine.symptom ,business - Abstract
Autoinflammatory diseases cause systemic inflammation which can result in damage to multiple organs. Organ damage can occur before the start of therapy, or when patients experience ongoing inflammation. A validated instrument to measure damage is essential to quantify damage in individual patients, and to compare disease outcomes in clinical studies. At this moment, there is no such instrument. In the context of the RaDiCEA project, a common damage index for Familial Mediterranean Fever (FMF), Cryopyrin Associated Periodic Syndromes (CAPS), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) and Mevalonate Kinase Deficiency (MKD) will be developed.
- Published
- 2015
- Full Text
- View/download PDF